Literature DB >> 10846590

Principles of HIV resistance testing and overview of assay performance characteristics.

D D Richman1.   

Abstract

HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several principles and biological factors impacting drug resistance testing are summarized. Considerations regarding quality control and validation of the performance of genotypic and phenotypic assays are also addressed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10846590

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  8 in total

1.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

2.  Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.

Authors:  R A Galli; B Sattha; B Wynhoven; M V O'Shaughnessy; P R Harrigan
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

4.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

5.  High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Authors:  R W Shafer; K Hertogs; A R Zolopa; A Warford; S Bloor; B J Betts; T C Merigan; R Harrigan; B A Larder
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Dual-reporter phenotypic assay for human immunodeficiency viruses.

Authors:  Keiko Kajiwara; Eiichi Kodama; Yasuko Sakagami; Takeshi Naito; Masao Matsuoka
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

7.  Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.

Authors:  Richard J Colonno; Alexandra Thiry; Kay Limoli; Neil Parkin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

8.  HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

Authors:  Max von Kleist; Stephan Menz; Hartmut Stocker; Keikawus Arasteh; Christof Schütte; Wilhelm Huisinga
Journal:  PLoS One       Date:  2011-03-24       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.